TSX higher on employment data
FORT WORTH - Sanara MedTech Inc. (NASDAQ:SMTI), a medical technology company focused on surgical, chronic wound and skin markets with a market capitalization of $309 million, announced Tuesday that Seth Yon will become President and Chief Executive Officer effective September 15, 2025. According to InvestingPro analysis, the company is currently trading above its Fair Value.
Yon, who currently serves as President and Chief Commercial Officer, will also join the company’s Board of Directors. Ron Nixon will transition from his current role but continue to serve as Executive Chairman.
According to the company’s statement, Yon has been with Sanara since March 2018, starting as Director of Sales before progressing through several leadership positions of increasing responsibility.
During Yon’s tenure in senior commercial roles, Sanara achieved annual net revenue growth of 53% on a compounded basis over the past three fiscal years, according to the company’s press release. The company maintains impressive gross profit margins of 91.76% and has shown continued momentum with revenue growth of 34.29% over the last twelve months.
"Working alongside Sanara’s talented team to improve patient outcomes and deliver value to the healthcare system has proven to be one of the greatest highlights of my 27-year career," Yon said in the announcement.
Prior to joining Sanara, Yon served as Vice President of Sales and Marketing for Iroquois Industrial Group from 2015 to 2018. He previously founded GreenerGrads and began his career at Jostens, Inc. He holds a Bachelor of Arts degree from Grand Valley State University.
Nixon, who will remain actively involved as Executive Chairman, stated he will focus on current initiatives in the company’s Sanara Surgical and Tissue Health Plus segments, along with other strategic aspects to support Yon in his new role.
Sanara MedTech markets and distributes various surgical and wound care products primarily in the North American advanced wound care and surgical tissue repair markets. InvestingPro analysis shows the company maintains strong financial health with a current ratio of 2.26, though it remains unprofitable over the last twelve months. For deeper insights into SMTI’s financial health and growth prospects, investors can access the comprehensive Pro Research Report, available exclusively on InvestingPro, covering over 1,400 US stocks.
In other recent news, Sanara MedTech reported strong financial results for the second quarter of 2025. The company achieved net revenue of $25.8 million, marking a 28% increase compared to the same period last year. This revenue figure surpassed H.C. Wainwright’s projection of $25.4 million. Despite posting a net loss of $2.0 million, or ($0.23) per share, the loss was smaller than the anticipated $2.9 million. The growth in revenue was largely attributed to robust sales in Sanara MedTech’s soft tissue and bone fusion product lines. In response to these results, H.C. Wainwright raised its price target for the company’s stock to $54, maintaining a Buy rating. These developments highlight Sanara MedTech’s positive momentum in the market.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.